Targeting the mitotic checkpoint to kill tumor cells

Aniek Janssen1, Geert J Kops, René H Medema

  • 1Department of Medical Oncology and Cancer Genomics Center, University Medical Center Utrecht, Universiteitsweg 100, 3584 CG, Utrecht, The Netherlands.

Hormones & Cancer
|April 9, 2011
PubMed

Insights

Cancer cells often have abnormal chromosome numbers (aneuploidy). Inhibiting the mitotic checkpoint in tumor cells increases chromosome missegregation and cell death, suggesting a potential anti-cancer therapy.

Area of Science:

  • Cell Biology
  • Cancer Research
  • Genetics

Background:

  • Aneuploidy, an abnormal chromosome number, is a common characteristic of cancer cells.
  • This arises from chromosome missegregation during mitosis, a frequent event in tumor cell divisions.
  • Chromosome instability (CIN) is prevalent in human tumors, leading to variegated aneuploidy.

Purpose of the Study:

  • To investigate if aneuploidy can be exploited as an anti-cancer therapeutic target.
  • To test the hypothesis that inhibiting the mitotic checkpoint could selectively harm tumor cells.

Main Methods:

  • Inactivation of the mitotic checkpoint using RNA interference (RNAi)-mediated depletion of Mps1.
  • Assessing the impact of mitotic checkpoint inactivation on chromosome segregation fidelity.
  • Quantifying cell death in tumor cells following checkpoint inhibition.

Main Results:

  • Depletion of Mps1 led to a significant increase in chromosome missegregation errors during mitosis.
  • This increase in segregation errors was directly correlated with enhanced cell death in tumor cells.
  • Inhibition of the mitotic checkpoint effectively induced cell death in cancer cells.

Conclusions:

  • The study supports the hypothesis that targeting the mitotic checkpoint is a viable anti-cancer strategy.
  • Exploiting chromosome missegregation through mitotic checkpoint inhibition shows promise for cancer therapy.
  • Mitotic checkpoint inhibition represents a potential therapeutic approach for treating aneuploid tumors.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...